Peripheral insulin resistance may predict exenatide treatment response in Parkinson’s disease
Objective: To explore if the glucagon-like peptide-1 (GLP-1) receptor agonist, exenatide could modify the course of Parkinson’s disease (PD) and if peripheral insulin resistance (IR) mightdifferentially impact on this. Background: Exenatide…Targeting IGF2 Signaling for Immune Modulation of Microglia in Parkinson’s Disease
Objective: We propose that IGF2 induces a distinct inflammatory phenotype in macrophages or microglia derived from Parkinson’s disease (PD) patients. Background: Microglia are the resident…Cognitive Effects of Istradefylline in Parkinson’s Disease: A 26-Week Open-Label Pilot Study
Objective: The objective of this study was to collect preliminary evidence whether istradefylline may improve cognition in Parkinson’s disease (PD) patients with cognitive impairment. Background:…Effect of Antihypertensive Agent Choice on Parkinson’s Disease Progression in Patients with Hypertension
Objective: To determine the effect of different classes of antihypertensive medications on Parkinson’s disease progression. Background: Cardiovascular risk factors such as hypertension can worsen Parkinson’s…Transcutaneous Vagus Nerve Stimulation for Gait and Motor Function in Parkinson’s Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Objective: To evaluate the effects of transcutaneous vagus nerve stimulation (tVNS) on gait, motor function, and freezing of gait (FOG) in patients with Parkinson’s disease…Updated Meta-analysis Assessing GLP-1 Agonists for Parkinson’s Disease
Objective: Evaluate the efficacy and safety of Glucagon-like peptide-1 (GLP-1) agonists on Parkinson’s disease (PD). Background: The idea of repositioning drugs used to treat PD…Serum based estimations of CFAH, Gelsolin, CNDP1 and DKK3 levels suggest involvement of multiple pathways in pathogenesis of Parkinson’s disease.
Objective: To estimate levels of complement factor H (CFAH), phosphorylated alpha-syn (p- a-syn), gelsolin, carnosine dipeptidase-1 (CNDP1) and DKK3 in serum of Parkinson’s disease (PD) patients…Basal Ganglia Physiomarkers of Non-motor Symptoms in Parkinson’s Disease: a Systematic Review
Objective: To systematically review the evidence linking basal ganglia local field potentials to non-motor symptoms in Parkinson’s disease. Background: Deep brain stimulation for Parkinson’s disease…Quantitative Measures of Cutaneous Phosphorylated Alpha-Synuclein: Powering a Disease Modification Clinical Trial In Parkinson’s Disease
Objective: To use a novel quantitative assessment of cutaneous P-SYN in a pilot study of patients with Parkinson’s disease (PD) and healthy volunteers (HVs) to…Relationship Between Motor Subtypes and Central and Peripheral Neurodegeneration in Early Parkinson’s Disease: A Study Using DAT SPECT and SUDOSCAN
Objective: To investigate the relationship between Parkinson’s disease (PD) motor subtypes and neurodegeneration in both the central and peripheral nervous systems using dopamine transporter single-photon emission…
- « Previous Page
- 1
- …
- 19
- 20
- 21
- 22
- 23
- …
- 436
- Next Page »